Hereditary Alpha‑Tryptasemia: Evidence‑Based Genetic and Clinical Insights

Genetic Basis

• Hereditary α‑tryptasemia (HαT) is caused by increased copy number (duplication or triplication) of the TPSAB1 gene, resulting in overproduction of α‑tryptase and formation of unique α/β‑tryptase heterotetramers with distinct physiochemical properties. 1

• Droplet‑digital PCR (ddPCR) testing of TPSAB1 copy number reliably identifies these duplications or triplications that encode α‑tryptase. 1

Clinical Manifestations

Cutaneous

• Patients with HαT may experience flushing, pruritus, urticaria, and vibratory urticaria. 1

Gastrointestinal

• Functional gastrointestinal disorders are common, including irritable bowel‑type symptoms, dysmotility, abdominal cramping, diarrhea, and other gut‑brain interaction manifestations. 1

Autonomic

• Dysautonomia, particularly postural orthostatic tachycardia syndrome (POTS), has been reported in individuals with HαT. 1

Musculoskeletal

• Joint hypermobility, arthritis, chronic musculoskeletal pain, and broader connective‑tissue abnormalities are associated with HαT. 1

Allergic

• A broad spectrum of allergies affecting the skin, respiratory tract, or cardiovascular system can occur in HαT patients. 1

Other

• Additional features include retained primary dentition and neuropsychiatric manifestations. 1

Diagnostic Approach

Systemic Mastocytosis Criteria (Differential Diagnosis)

• The World Health Organization criteria for systemic mastocytosis require bone‑marrow findings such as:
  
  • Major criterion – multifocal dense mast‑cell infiltrates.
  • Minor criteria – abnormal mast‑cell morphology, expression of CD25/CD2, presence of the KIT D816V mutation, and persistently elevated basal serum tryptase > 20 ng/mL.
• Meeting one major and at least one minor criterion, or three minor criteria, confirms systemic mastocytosis. 2

Emerging Prenatal Testing

• Technically feasible prenatal genetic diagnosis (e.g., via amniocentesis or chorionic villus sampling combined with DNA amplification) exists for many genetic conditions, although no routine prenatal test for HαT is currently recommended. 3

All bullet points are supported by the cited references indicated in brackets.

Elevated Tryptase Levels: Benign Conditions and Diagnostic Considerations

Introduction to Benign Elevated Tryptase

• Elevated baseline tryptase levels are considered benign when they occur in the absence of systemic mastocytosis, mast cell activation syndrome, or ongoing mast cell degranulation, specifically in conditions like hereditary alpha-tryptasemia, cutaneous mastocytosis in children, or as an isolated finding in 4-6% of the general population without associated symptoms or organ damage 4

Clinical Contexts Where Elevated Tryptase is Benign

• Hereditary alpha-tryptasemia involves duplications or triplications in the TPSAB1 gene encoding α-tryptase and is found in 4-6% of the general population, with patients typically having baseline tryptase levels above 8 ng/mL without meeting criteria for systemic mastocytosis 4
• Pediatric cutaneous mastocytosis is generally benign with high spontaneous regression rates: 75% of mastocytomas and 56% of urticaria pigmentosa cases resolve completely 5, 6
• Elevated tryptase >20 μg/L in children with cutaneous disease alone indicates increased mast cell burden but typically does not progress to systemic disease 5, 6

Critical Thresholds and Distinctions

• Tryptase >200 ng/mL indicates high mast cell burden and is classified as a B-finding in systemic mastocytosis, requiring close observation and possible hospitalization 7, 4
• Persistently elevated tryptase >20 ng/mL serves as a minor diagnostic criterion for systemic mastocytosis and warrants bone marrow evaluation 7, 4

Diagnostic Evaluation

• The National Comprehensive Cancer Network recommends confirming baseline tryptase levels are truly baseline (measured >24 hours after any acute event, not during symptoms) 8
• The American Journal of Clinical Dermatology suggests assessing the level of tryptase, with <15 ng/mL generally considered normal, 8-20 ng/mL prompting consideration of hereditary alpha-tryptasemia testing, and >20 ng/mL requiring evaluation for systemic mastocytosis 9, 4
• The Journal of Allergy and Clinical Immunology notes that a ratio of total tryptase to β-tryptase of 20 or greater is consistent with systemic mastocytosis, but this baseline elevation without acute rises is not immediately dangerous 9, 10